Small RNA sequencing and functional characterization reveals microrna-143 tumor suppressor activity in liposarcoma

Cancer Research

Volumn 71, Issue 17, 2011, Pages 5659-5669

  Ugras, Stacy ^a   Brill, Elliott ^a   Jacobsen, Anders ^a   Hafner, Markus ^a   Socci, Nicholas D ^a   DeCarolis, Penelope L ^a   Khanin, Raya ^a   O'Connor, Rachael ^a   Mihailovic, Aleksandra ^a   Taylor, Barry S ^a   Sheridan, Robert ^a   Gimble, Jeffrey M ^b   Viale, Agnes ^a   Crago, Aimee ^a   Antonescu, Cristina R ^a   Sander, Chris ^a   Tuschl, Thomas ^a   Singer, Samuel ^a,c  

^a ROCKEFELLER UNIVERSITY   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); MICRORNA; POLO LIKE KINASE 1; PROTEIN BCL 2; PROTEIN REGULATOR OF CYTOKINESIS 1; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINESIS; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOSARCOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA HYBRIDIZATION; RNA SEQUENCE; UPREGULATION;

ADIPOGENESIS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LIPOSARCOMA; MICRORNAS;

EID: 80052207613     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0890     Document Type: Article

References (35)

1. Mack TM. Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer 1995;75:211-44.
2. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010;42:715-21.
3. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003;238:358-70; discussion 70-1.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
5. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
6. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466:835-40.
7. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
8. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14.
9. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009;136:586-91.
10. Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 2009;16:533-46.
11. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-9.
12. Gimble J, Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy 2003;5:362-9. (Pubitemid 37369023)
13. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, et al. Gene expression profiling of liposarcoma identifies distinct biologicaltypes/ subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007;67:6626-36. (Pubitemid 47105508)
14. Hafner M, Renwick N, Pena J, Mihailović A, Tuschl T. Barcoded cDNA libraries for miRNA profiling by next-generation sequencing. In:Hartmann RK, Bindereif A, Schön A, Westhof A, editors. Handbook of RNA Biochemistry, 2nd ed. Wennheim, Germany: Wiley-VCH Verlag GmbH; 2010. In press.
15. Pena JT, Sohn-Lee C, Rouhanifard SH, Ludwig J, Hafner M, Mihailovic A, et al. miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat Methods 2009;6:139-41.
16. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N. Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A 2006;103:2746-51.
17. Jacobsen A, Wen J, Marks DS, Krogh A. Signatures of RNA binding proteins globally coupled to effective microRNA target sites. Genome Res 2010;20:1010-9.
18. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3. Epub 2004 Feb12.
19. Cerami E, Demir E, Schultz N, Taylor BS, Sander C. Automated network analysis identifies core pathways in glioblastoma. PLoS One 2010;5:e8918.
20. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009;460:705-10.
21. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004;279:52361-5. (Pubitemid 39656612)
22. Neef R, Gruneberg U, Kopajtich R, Li X, Nigg EA, Sillje H, et al. Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1. Nat Cell Biol 2007;9:436-44. (Pubitemid 46511077)
23. Schmidt A, Durgan J, Magalhaes A, Hall A. Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from cytokinesis. EMBO J 2007;26:1624-36. (Pubitemid 46480950)
24. Wolfe BA, Takaki T, Petronczki M, Glotzer M. Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation. PLoS Biol 2009;7:e1000110.
25. Wasch R, Hasskarl J, Schnerch D, Lubbert M. BI-2536-targeting the mitotic kinase Polo-like kinase 1 (Plk1). Recent Results Cancer Res 2010;184:215-8.
26. Schoffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 2010;46:2206-15.
27. Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 2010;70:1513-23.
28. Lin T, Dong W, Huang J, Pan Q, Fan X, Zhang C, et al. MicroRNA- 143 as a tumor suppressor for bladder cancer. J Urol 2009;181:1372-80.
29. Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 2007;26:311-20. (Pubitemid 46799180)
30. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009;28:1385-92.
31. Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F. microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep 2010;24:1363-9.
32. Gobble RM, Qin LX, Brill ER, Angeles CV, Ugras S, O'Connor RB, et al. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res 2011;71:2697-705.
33. Mollinari C, Kleman JP, Saoudi Y, Jablonski SA, Perard J, Yen TJ, et al. Ablation of PRC1 by small interfering RNA demonstrates that cytokinetic abscission requires a central spindle bundle in mammalian cells, whereas completion of furrowing does not. Mol Biol Cell 2005;16:1043-55. (Pubitemid 40349544)
34. Mollinari C, Kleman JP, JiangW, Schoehn G, Hunter T, Margolis RL. PRC1 is a microtubule binding and bundling protein essential to maintain the mitotic spindle midzone. J Cell Biol 2002;157:1175-86. (Pubitemid 34847788)
35. Santamaria A, Neef R, Eberspacher U, Eis K, Husemann M, Mumberg D, et al. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 2007;18:4024-36. (Pubitemid 47519493)